Drugs / IBI363
Trials 19 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06610799 | Oct 2024 → Jun 2025 overdue | — | Xiangdong Cheng | Recruiting | No outcome recorded |
| Phase 1 | NCT06468098 | Jun 2024 → Jun 2025 overdue | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06717880 | Jul 2023 → Jul 2025 overdue | cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 1 | NCT05460767 | Aug 2022 → Mar 2024 | lymphoma | Innovent Biologics (Suzhou) Co. Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05290597 | Aug 2022 → Jan 2026 overdue | lymphoma | Innovent Biologics (Suzhou) Co. Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07361991 | Mar 2026 → Sep 2028 expected | — | The First Affiliated Hospital of Zhengzhou University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07307053 | Jan 2026 → Jan 2029 expected | high grade malignant neoplasm, metastatic neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07342725 | Jan 2026 → Dec 2027 expected | malignant pancreatic neoplasm | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06081907 | Dec 2023 → Dec 2026 expected | neoplasm | Hunan Province Tumor Hospital | Recruiting | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT07402070 | Feb → Dec 2026 expected | non-small cell lung carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07408635 | Jan 2026 → Jun 2028 expected | non-small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Recruiting | No outcome recorded |
| Phase 2 | NCT07289048 | Dec 2025 → Dec 2027 expected | small cell lung carcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07325630 | Nov 2025 → May 2026 overdue | — | Zhejiang Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07124793 | Aug 2025 → Sep 2026 expected | — | Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07122687 | Aug 2025 → Nov 2026 expected | non-small cell lung carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06797297 | Feb 2025 → Mar 2026 overdue | melanoma | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06620822 | Sep 2024 → Sep 2026 expected | non-small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06281678 | Apr 2024 → Mar 2026 overdue | colorectal cancer, melanoma, non-small cell lung carcinoma, renal cell carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06081920 | Oct 2023 → Jun 2025 overdue | melanoma | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI363 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06281678 ↗ |
| Action | Inhibit | “checkpoint blockade” NCT05460767 ↗ |
| Modality | Protein / enzyme biologic | “a mutated IL-2 cytokine fused to an anti-PD-1 antibody” NCT05290597 ↗ |
| Route | Intravenous | “IBI363 will be administered as an intravenous (IV) infusion every 2 weeks or every 3 weeks.” NCT06281678 ↗ |